Sodium tanshinone IIA sulfonate protects rat myocardium against ischemia-reperfusion injury via activation of PI3K/Akt/FOXO3A/Bim pathway

Mei-qi ZHANG\textsuperscript{1,8}, Yue-liang ZHENG\textsuperscript{1,8}, Huan CHEN\textsuperscript{1}, Jian-feng TU\textsuperscript{1}, Ye SHEN\textsuperscript{1}, Jun-ping GUO\textsuperscript{1}, Xiang-hong YANG\textsuperscript{1}, Shu-ren YUAN\textsuperscript{2}, Liang-zhong CHEN\textsuperscript{2}, Jing-jie CHAI\textsuperscript{2}, Jian-hong LU\textsuperscript{2}, Chang-lin ZHAI\textsuperscript{2,*}

\textsuperscript{1}Department of Emergency Intensive Care Unit, Zhejiang Provincial People’s Hospital, Hangzhou 310014, China; \textsuperscript{2}Department of Cardiology, First People’s Hospital of Tongxiang, Hangzhou 314500, China

**Aim:** To investigate the mechanisms underlying the protective effects of sodium tanshinone IIA sulfonate (STS) in an ischemia-reperfusion (I/R)-induced rat myocardial injury model.

**Methods:** Male SD rats were iv injected with STS, STS+LY294002, or saline (NS) for 15 d. Then the hearts were subjected to 30 min of global ischemia followed by 2 h of reperfusion. Cardiac function, infarction size and area at risk were assessed. Cell apoptosis was evaluated with TUNEL staining, DNA laddering and measuring caspase-3 activity. In addition, isolated cardiomyocytes of neonatal rats were pretreated with the above drugs, then exposed to H\textsubscript{2}O\textsubscript{2} (200 \textmu mol/L) for 1 h. Cell apoptosis was detected using flow cytometric assay. The levels of p-Akt, p-FOXO3A and Bim were examined with immunoblotting.

**Results:** Compared to NS group, administration of STS (20 mg/kg) significantly reduced myocardial infarct size (40.28\%±5.36\% in STS group vs 59.52\%±7.28\% in NS group), and improved the myocardial function as demonstrated by the increased values of \(\frac{dP}{dt_{\text{max}}}, \text{LVDP}\) and coronary flow at different reperfusion time stages. Furthermore, STS significantly decreased the rate of apoptotic cells (15.11\%±3.71\% in STS group vs 38.21\%±7.83\% in NS group), and reduced caspase-3 activity to nearly a quarter of that in NS group. Moreover, STS significantly increased the phosphorylation of Akt and its downstream target FOXO3A, and decreased the expression of pro-apoptotic gene Bim. Co-treatment with the PI3K inhibitor LY294002 (40 mg/kg) partially countered the protective effects induced by STS treatment. In isolated cardiomyocytes, STS exerted similar protective effects as shown in the ex vivo I/R model.

**Conclusion:** STS pretreatment reduces infarct size and improves cardiac function in an I/R-induced rat myocardial injury model via activation of Akt/FOXO3A/Bim-mediated signal pathway.

**Keywords:** sodium tanshinone IIA sulfonate; heart attack; myocardial ischemia-reperfusion; apoptosis; Akt; FOXO3a; Bim; PI3K; LY294002

Introduction

Myocardial ischemia-reperfusion (I/R) injury is a major complication that occurs during heart attack, cardiopulmonary bypass surgery, and heart transplantation\textsuperscript{[9]}, which ultimately leads to an irreversible fatal injury. Apoptosis plays a crucial role in cardiac dysfunction following acute myocardial infarction\textsuperscript{[2]}. Various strategies aimed at preventing or mitigating the extent of apoptosis have been attempted to protect the heart against I/R injury. However, all attempts to date have exhibited limited efficacy. Developing new therapies for myocardial I/R injury represents an urgent and significant research interest\textsuperscript{[3]}.

Apoptotic cell death can be induced by ischemia alone due to a lack of oxygen supply, and reperfusion accelerates the apoptotic death process that is initiated during the preceding ischemic period\textsuperscript{[4]}. Thus, studies have suggested that the apoptotic component of cell death is either triggered or accelerated during the reperfusion phase\textsuperscript{[5]}. I/R has been shown to activate the pro-survival PI3K/Akt kinase signaling cascades, which have been implicated in cellular survival, through their recruitment of protective anti-apoptotic proteins. The serine/threonine-specific protein kinase Akt (also known as protein kinase B) is a potent survival factor and is one of the primary kinases that is activated by PI3K, which, in turn, is activated by several myocardial protective ligand-receptor systems,
including insulin and angiotensin II. Important downstream targets of Akt are members of the FOXO subfamily of forkhead transcription factors. This FOXO subfamily includes at least the following three members: FOXO1, FOXO3A, and FOXO4, all of which can be inactivated by Akt-dependent phosphorylation\cite{16}. Among these three FOXO members, FOXO3A regulates cellular apoptosis by inducing the pro-apoptotic gene Bim in cancer cells, neurons, and endothelial progenitor cells\cite{7,8}. Weston et al\cite{9} demonstrated that the inhibition of the PI3K/Akt pathway resulted in an increase in Bim expression, implying that by phosphorylating Akt, the activation of the PI3K-Akt pathway exerts an inhibitory influence on Bim expression, thereby preventing apoptosis.

Sodium tanshinone IIA sulfonate (STS)\cite{10} is a water-soluble derivative of tanshinone IIA\cite{11,12}, which is a major lipophilic component that is extracted from the root of the Salvia miltiorrhiza (Fam Labiateae) plant. This plant is well-known in traditional Chinese medicine and is used for the treatment of various cardiovascular diseases, such as myocardial infarctions and coronary heart disease. Recent studies\cite{13,14} have revealed that STS elicits protective effects on cardiomyocytes against oxidative stress-mediated apoptosis in preclinical experiments. Hence, the cardioprotective effect of STS may represent therapeutic potential for clinical applications. Given the cardioprotective effect of the PI3K/Akt pathway in the I/R rat model, we hypothesized that the cardioprotective effect of STS might involve the activation of the PI3K/Akt pathway. Therefore, the aim of this study was to: investigate the cardioprotective effect of STS against myocardial I/R injury in the rat heart and: to identify whether the underlying protective mechanisms are associated with the Akt/FOXO3A/Bim-mediated apoptosis pathway both in vivo and in vitro.

Materials and methods
Animal maintenance and treatment
All procedures and studies in this article were in compliance with the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Science and published by the US National Institutes of Health (Publication No 85-23, revised 1996). The experimental protocol was approved by the Committee on Animal Experiments of Zhejiang University School of Medicine. Male Sprague-Dawley rats weighing between 250 and 300 g were obtained from the Experimental Animal Center of Hangzhou, Zhejiang Province (China) and were allowed free access to laboratory chow and tap water in day-night quarters at 25°C.

The rats were randomized into the following three groups, which included eight animals each: (1) I/R rats pretreated with saline (NS group); (2) I/R rats pretreated with STS at a dose of 20 mg/kg (STS group); and (3) I/R rats co-pretreated with 20 mg/kg STS and 40 mg/kg PI3K inhibitor LY294002 (STS+LY294002 group).

STS treatment
STS was obtained from the Department of Pharmacology, Zhejiang University of Traditional Chinese Medicine. It was dissolved in PBS at a concentration of 10 mg/mL and was prepared freshly every day. Each animal received intravenous injection of STS once per day at the same time. After 15 d of injections, the ex vivo ischemic induction and isolation of the hearts were performed.

PI3K activity inhibition
To investigate the role of the PI3K/Akt pathway in myocardial I/R-induced apoptosis, a specific PI3K inhibitor was injected. The inhibitor, LY294002, was purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA) and dissolved in DMSO and PBS. LY294002 (40 mg/kg dissolved in 25% dimethylsulfoxide and diluted 1:10 in PBS) was administered intravenously in the tail vein at 30 min prior to the ischemia and reperfusion processes.

Isolated working heart preparation
The isolated myocardial I/R model was established as previously described\cite{15}. Briefly, the rats were anesthetized using pentobarbital sodium (80 mg/mL ip) and a heparinized 0.9% saline solution (500 IU/kg per day, iv). After a sufficient depth of anesthesia, thoractomy was performed, and the hearts were perfused in the retrograde Langendorff mode at 37°C at a constant perfusion pressure of 100 cmH2O (10 kPa) for 5 min washout period. A modified Krebs-Henseleit bicarbonate buffer (KHB), containing (in mmol/L) 118 NaCl, 4.7 KCl, 1.7 CaCl2, 25 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, and 10 glucose, was used in this perfusion buffer. The Langendorff preparation was switched to the working mode following the washout period, as previously described\cite{16,17}. The working mode was performed by switching the flow from the aortic root to the left atrium with a constant preload of 17 cmH2O and an afterload of 100 cmH2O\cite{16,17}. After reaching a steady-state of cardiac function, the baseline functional parameters were recorded. The circuit was then switched back to the retrograde mode, and the hearts were perfused for 15 min with KHB buffer. Next, the hearts were subjected to global ischemia for 30 min followed by 2 h of reperfusion. The first 10 min of reperfusion were performed in the retrograde mode to allow for postischemic stabilization. Subsequently, the reperfusion was performed in the anterograde-working mode to allow for the assessment of functional parameters, which were recorded at 30, 60, 90, and 120 min of reperfusion.

Determination of cardiac function
Aortic pressure was measured using a pressure transducer (Micro-Med, USA) connected to a sidearm of the aortic cannula, and the signal was amplified using a Heart Performance Analyzer (model 400; Micro-Med, USA). The heart rate (HR), the first derivative of developed pressure (dp/dt) and the left ventricular developed pressure (LVDP; systolic pressure minus the end-diastolic pressure in mmHg) were all derived or calculated from the continuously obtained pressure signal. Coronary flow (CF) was measured by a timed collection of the coronary effluent dripping from the heart.
Estimation of infarct size and area at risk
At the end of reperfusion, a 1% (w/v) solution of triphenyl tetrazolium chloride (TTC) in phosphate buffer was infused into the aortic cannula at 37°C. The hearts were quickly excised and stored at -70°C. Sections of frozen heart were fixed in 10% formalin, placed between two cover slips, and digitally imaged using a Epson scanner. The infarcted area remained unstained, whereas the non-infarcted area stained red. Negatively stained areas indicated infarcted myocardium. Next, the coronary arteries were retied at the site of previous occlusion, and the hearts was perfused with a 2% solution of Evans blue dye to delineate the ischemic area (area at risk). The areas of infarcted, ischemic and non-ischemic myocardium were measured and calculated using NIH image analysis software, and from these measurements, the infarcted size (IS) was calculated as a percentage of the area at risk (AAR). The AAR was expressed as a percentage of the left ventricles (LVs).

Histological examination
The frozen left ventricle fixed by formalin were then embed- ded in paraffin and cut into transverse sections at a thickness of 6 μm, with a routine follow-up procedure. The sections were stained with hematoxylin and eosin for light microscopic examination. An observer that was blinded to the experimental conditions of animals recorded the data.

Determination of cardiomyocyte apoptosis and caspase-3 activity
The terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) assay was performed, according to the manufacturer’s protocols (Roche, Switzerland). The cells exhibiting clear nuclear labeling were defined as TUNEL positive cells. For each slide, the color images of 10 separate fields were captured randomly and digitized. The numbers of TUNEL positive cells in each group were counted separately using ImageJ software.

The caspase-3 activity was measured using ApoAlert Cas- pase-3 Assay Plate (Clontech, Mountain View, CA, USA), according to the manufacturer’s protocols. Substrate cleavage was monitored fluorometrically using a SpectraMax Gemini spectrophotometer (Molecular Devices, Sunnyvale, CA, USA) at excitation and emission wavelengths of 350 and 450 nm, respectively.

Subcellular cytoplasmic and mitochondrial fractionation
For subcellular fractionation, cell lysates were produced using a glass tissue grinder (Wheaton, Millville, NJ, USA). The lysates were centrifuged at 750×g for 10 min at 4°C and subsequently at 8000×g for 20 min at 4°C. The resulting pellets were used to obtain the mitochondrial fraction. The supernatant was centrifuged further at 100000×g for 60 min at 4°C and was used for the analysis of the cytosolic fraction.

Quantitative real-time PCR for detection of Bim mRNA
Total RNA was isolated from the left ventricles by TRIZOL (Gibco-BRL, USA), according to the manufacturer’s protocols, and its quality was evaluated on a 1% denaturing agarose gel to ensure the presence of the 28S and 18S ribosomal bands. The total RNA concentrations were determined by spectrophotometry. A total of 1 μg of RNA was incubated in a reverse transcription mixture at 42°C for 50 min, followed by PCR amplification using the specific primers (synthesized by Invitrogen Company, USA). The following primers were used: Bim FW: 5’-CCCCCTACCTCCCTAACAGCA-3’; RV: 5’-GACCGGAGATGAATCGTAAACAG-3’; GAPDH FW: 5’-ATCCGTGTGGATCTGACATG-3’, RV: 5’-TGTC- CAGGTTCTTTACTCC-3’. The PCR conditions were 95°C for 15 s followed by 30 cycles of amplification consisting of 95°C for 5 s and 60°C for 30 s. The reactions were performed in triplicate, and the results were averaged. Each value was normalized to GAPDH mRNA levels to control for variations in the amount of input cDNA. The relative expression levels of the genes compared with the control group were calculated using the 2^(-ΔΔCt) method.

Extraction of protein and Western blot assay
Freshly frozen myocardial tissue samples were homogenized in RIPA lysis buffer, and centrifuged to extract the total protein. The Bradford assay (Bio-Rad Laboratories, USA) was used to quantitate protein concentrations. Total protein (50 μg) was separated on 12% SDS-PAGE gels and transferred to nitrocellulose filter membranes. Primary antibodies against Akt, phosphorylated Akt (p-Akt), FOXO1, p-FOXO1, FOXO3A, p-FOXO3A, FOXO4, p-FOXO4, cytochrome c, and Bim (Abcam, UK) were used at an appropriate dilution ratio, followed by peroxidase-coupled secondary antibodies (Sigma, USA, 1:10000). The blots were visualized by enhanced chemiluminescence system using an ECL kit (Roche, USA). The signals were quantified by densitometry using imaging software (BioSens Digital Imaging 5, Shanghai Bio-Tech Inc, Shanghai, China).

Neonatal rat cardiac cell cultures
Cardiac cells were isolated from 1-to-3-d-old neonatal Wistar rats and were cultured as previously described[19]. Briefly, the rats were sacrificed and their hearts were excised. After scalpel homogenization, the heart tissue samples were incubated in 0.25% (w/v) trypsin overnight at 4°C after treatment with 0.1% (w/v) collagenase for 20 min at 37°C. Cardiomyocytes were enriched by centrifugation and plated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal calf serum at 37°C and 5% (v/v) CO₂ for 72 h. The cardiomyocytes were allowed to adhere overnight in serum-deprived medium prior to treatment.

Drug treatment and cardiomyocyte injury induced by exposure to H₂O₂
To evaluate the protective effects of STS, cells were pretreated for 12 h with 3 μg/mL STS alone or 3 μg/mL STS and 10 μmol/L LY294002 at 1×10⁶ cells/well in six-well plates, and washed twice with D-Hank’s solution prior to the addition of H₂O₂. The cardiomyocytes were then exposed to 200 μmol/L H₂O₂ for 1 h[19]. The control cells were also incubated under
identical conditions.

Flow cytometric analyses for apoptosis
Apoptotic cells were detected by annexin V and 7-AAD double-labeling following the manufacturer’s protocol, as previously described[38]. Briefly, cells were harvested at the indicated time periods, washed twice with cold phosphate-buffered saline (PBS), and then re-suspended in 500 µL binding buffer. Next, the cells were stained with 5 µL of annexin V-fluorescein isothiocyanate (FITC) and 5 µL of 7-AAD for 15 min at room temperature in the dark. Flow cytometry (BD FACSAria II) was used to assess the percentage of cell apoptosis.

Statistical analysis
The results were analyzed using the SPSS statistical package (ver 12.0; IBM, USA) and are presented as the mean values±SEM. The data were compared using Tukey’s honest significance test and a one-way analysis of variance (ANOVA). P-values <0.05 were considered statistically significant.

Results
Protective effects of STS on myocardial function
To evaluate the protective effects of STS on heart against ischemic injury, we established a rat model of in vitro global I/R. As shown in Figure 1A, pre-treatment with STS significantly reduced the myocardial infarction sizes after I/R compared with that observed in the NS group (40.28%±5.36% vs 59.52%±7.28%, P<0.05). This effect was partially abrogated by co-treatment with LY294002 (50.76%±5.49% in STS+LY294002 group vs 40.28%±5.36% in STS group, P<0.05). However, AAR, which was defined as the myocardial tissue within the perfusion bed distally to the culprit lesion of the infarct-related coronary artery, was similar among all of the groups.

Myocardial functions (dP/dt max, LVDP, and CF) were significantly enhanced both at the baseline (prior to reperfusion) as well as during reperfusion in the STS group compared with the NS group. However, no significant difference was observed in HR (Figure 1B) among the three groups during I/R. The STS group exhibited a significant increase in dP/dt max, both at baseline and after 30 min of ischemia (Figure 1C) throughout the reperfusion period compared with the control (2984±274 vs 2493±209 mmHg/s 30 min post reperfusion). A similar pattern was observed in LVDP as well as in coronary flow (Figure 1D and 1E) in the STS group compared with the control. As expected, co-treatment with LY294002 in STS+LY294002 group in part abolished the protective effect elicited by STS treatment (Figure 1C–1E). These results indicated the PI3K/Akt-dependent cardioprotective effects of STS.

I/R-induced apoptosis is alleviated by STS pretreatment
The representative photograph show that TUNEL-positive cardiomyocytes were more frequently observed in the NS group and STS+LY294002 group compared to the STS group. Semi-quantitative analysis revealed that the incidence of TUNEL-positive cells was significantly reduced in the STS group compared to the NS group (15.11%±3.71% vs 38.21%±7.83%, P<0.05). When co-treated with LY294002 in the STS+LY294002 group, the percentage of TUNEL-positive cells was significantly increased compared to the STS group (22.08%±5.22% vs 15.11%±3.71%, P<0.05) (Figure 2A).

Mitochondrial dysfunction plays an important role in ischemia-reperfusion-induced cardiomyocyte apoptosis injury. Thus, we further assessed cytosolic and mitochondrial cytochrome c protein levels by immunoblotting analysis. As indicated in Figure 2B, we observed that in the NS group, cytochrome c was predominantly found within the cytosolic fraction, reflecting an active apoptotic process. Compared to the NS group, a significant decrease in cytochrome c within the cytosolic fraction accompanied by an increase within the mitochondrial fraction was observed in the STS group. Moreover, co-treatment with LY294002 reversed the effect of STS on the subcellular distribution of cytochrome c between the cytosolic and mitochondrial fractions. However, the reversal did not reach the level observed in the NS group. There was no significant difference in the total expression levels of cytochrome c between the three groups (Figure 2B).

The internucleosomal DNA fragmentation of cardiomyocytes represents a hallmark of apoptotic cell death. Negligible levels of DNA laddering were observed in the STS group, whereas DNA laddering was clearly detected in the NS and STS+LY294002 groups after 2 h of reperfusion. STS treatment significantly decreased the appearance of DNA laddering induced by I/R, which was counteracted by co-treatment with LY294002 (Figure 2C).

As an executioner caspase, caspase-3 is activated in apoptotic cells both by extrinsic (death ligand) and intrinsic (mitochondrial) pathways. The caspase-3 zymogen exhibits virtually no activity until it is cleaved by an initiator caspase following apoptotic signaling events. As shown in Figure 2D, the caspase-3 activity was significantly reduced in the STS group compared to the NS group, and co-treatment with LY294002 in the STS+LY294002 group significantly enhanced caspase-3 activity compared to that observed in STS group. These results demonstrated that the administration of STS significantly alleviated the I/R-induced myocardial cell apoptotic injury in the rats via the activation of a PI3K-dependent signaling pathway.

The PI3K/Akt pathway is involved in the protective effect of STS
STS treatment significantly increased the phosphorylated Akt (p-Akt) levels in myocardial tissues that were exposed to I/R compared to the NS group. The levels of p-Akt were significantly reduced when the PI3K/Akt inhibitor LY294002 was applied. The total Akt levels (t-Akt) remained unchanged among the three groups (Figure 3). These results imply that the PI3K/Akt pathway is involved in the STS-induced protective effects during I/R. STS treatment triggered PI3K activity that further activated the downstream potent survival factor phosphorylated Akt.
STS treatment induces FOXO3A phosphorylation but elicits no effect on FOXO1 and FOXO4

Mammalian forkhead members of the class O (FOXO) transcription factors, including FOXO1, FOXO3a, and FOXO4, are implicated in the regulation of several biological processes, such as stress resistance, metabolism, cell cycle, and apoptosis. To investigate which of the FOXO family member might be activated by STS treatment, we assessed the phosphorylation levels of each FOXO family member, including FOXO1, FOXO3A, and FOXO4. As shown in Figure 4, the levels of phosphorylated FOXO3A were significantly elevated in the STS group compared with that observed in the NS group (7.24±1.42-fold, P<0.05). Co-treatment with LY294002 in the STS+LY294002 group significantly reduced the expression of phosphorylated FOXO3a in STS group, although the levels were still increased compared to that observed in NS group (2.94±0.63-fold, P<0.05). Notably, the administration of STS did not alter the levels of phosphorylated FOXO1 and FOXO4 proteins among each group. Pre-treatment with STS alone or with LY294002 did not affect the total levels of FOXO1, FOXO3A or FOXO4 proteins. These results indicated that the protective effect of STS was associated with Akt-mediated FOXO3a signaling pathway, but not FOXO1 or FOXO4.

STS down-regulates Bim expression in a PI3K-dependent signaling pathway

The down-regulation of both mRNA and protein levels of Bim were observed in the STS group compared to the NS group. Moreover, as expected, co-treatment with LY294002 increased the mRNA and protein expression levels of Bim, which was
still reduced compared to the NS group (Figure 5A). The representative micrographs of rat myocardial IHC staining of Bim at 2 h after reperfusion are shown in Figure 5B. The average nuclear and cytoplasmic staining intensity of Bim was significantly reduced compared with that observed in the NS group. Co-treatment with LY294002 increased the average nuclear and cytoplasmic staining intensity of Bim, which was still reduced compared to the NS group. These results indicated that pre-treatment with STS down-regulated the expression of Bim in a PI3K/Akt-dependent signaling pathway.

The in vitro effect of STS on phospho-Akt, phospho-FOXO3A, and Bim expression

There were no significant differences in phospho-Akt, phospho-FOXO3A or Bim expression between the normal neonatal rat cardiac cells and the H$_2$O$_2$-induced control group. Pre-treatment with STS significantly increased the levels of phospho-Akt and phospho-FOXO3A but elicited no effect on the expression levels of total Akt and FOXO3A (Figure 6A). Moreover, STS decreased the expression of Bim at the mRNA
and protein levels compared to H$_2$O$_2$-induced control group (Figure 6B). Co-treatment with STS and LY294002, however, partially counteracted the effects elicited by the addition of STS alone.

**The in vitro effect of STS on apoptosis induced by H$_2$O$_2$**

Flow cytometric analysis of Annexin V/7-AAD staining of neonatal rat cardiac cells revealed that 28.3% of cells were in the early stages of apoptosis at 1 h of exposure to H$_2$O$_2$. STS...
treatment significantly decreased the extent of cardiomyocyte apoptosis compared to H2O2-induced control group (15.92%±3.36% vs 28.33%±4.17%). However, apoptosis was significantly increased by co-treatment with STS and LY294002 compared to STS treatment alone (21.59%±3.87% vs 15.92%±3.36%) (Figure 7A, 7B).

The caspase-3 activity was significantly increased in cells exposed to H2O2 compared with the normal cell group. STS treatment significantly decreased caspase-3 activity compared with the H2O2-induced control group. Co-treatment with STS and LY294002, however, significantly increased caspase-3 activity compared with STS treatment alone (Figure 7C).

Discussion
In this study, we demonstrated that in vivo and in vitro STS treatment elicited a protective effect against myocardial I/R-and H2O2-induced injury in rats and, furthermore, that the activation of a PI3K/Akt/FOXO3A/Bim-mediated anti-apoptotic pathway is involved in this protective process. According to our findings, the protective effect of STS in cardiac function following reperfusion was reduced in the presence of LY294002 (Figure 1). Concurrently, STS significantly increased p-Akt levels in the myocardial tissue samples and the neonatal rat cardiac cells, an increase that was in part abolished by LY294002 treatment (Figure 3, 6). These results revealed that the PI3K/Akt signaling pathway is involved in the protective effect of STS. Moreover, Forkhead transcription factor FOXO3A, but not FOXO1 or FOXO4, was phosphorylated and might play a role as a downstream effector of Akt in mediating the protective effect of STS (Figure 4, 6). Apoptosis in cardiomyocytes induced by I/R or exposure to H2O2 was significantly reduced when the cells were treated with STS but was enhanced following co-treatment with LY294002 (Figure 2, 7). This protective mechanism of STS involves the inhibition of the apoptosis-related activation of caspase-3, cytochrome c release, and the down-regulation of the Bim expression (Figure 2, 5, 6, 7). Thus, our study indicated that the protective effect of STS is associated with the PI3K/Akt/FOXO3A/Bim-mediated anti-apoptotic signaling pathway, a finding that is consistent with the results of previous studies.[5, 20, 21, 22].

STS is a predominant effective derivative of Salvia miltiorrhiza (known as “Danshen” in Traditional Chinese Medicine). Experimental and clinical evidence have shown that STS reduces heart infarct size and protects cardiac tissue against I/R injury.[23, 24]. Salvianolic acid A (SAA), another major active component of Danshen, elicits a marked protective effect on
myocardial ischemia-reperfusion injury and attenuates \( \text{H}_2\text{O}_2 \)-induced apoptosis. The cardioprotective effect of SAA is related to its ability to reduce myocardial cell apoptosis and damage induced by oxidative stress\(^{[25]}\). Several mechanisms have been reported to be involved in the cardioprotective effects of STS against cardiovascular injury. STS inhibits the formation of reactive oxygen species in rat heart mitochondria\(^{[26]}\), inhibits Ca\(^{2+}\) overload in cardiomyocytes\(^{[24]}\), depresses Na\(^{+}\)-K\(^{+}\)-ATPase activity in cardiac-derived microsomes\(^{[27]}\), and improves the conditions of hemorheologic effects, including the whole blood viscosity, fibrinogen, and D-dimer\(^{[28]}\). A previous study has indicated the role of PI3K/Akt in mediating STS-induced cardioprotection following myocardial I/R\(^{[29]}\), which is consistent with our findings. PI3K/Akt is known to mediate cytoprotective effects by regulating many downstream signals, including PKC, PI3K, or ERK1/2 pathways. Therefore, it is possible that the protective effect elicited by STS might be mediated by multiple signaling pathways, a possibility that requires further investigation in future studies.

The FOXO subfamily of forkhead transcription factors represents a downstream target of Akt. FOXO transcription factors have been implicated in regulating diverse cellular functions, including differentiation, metabolism, proliferation, and apoptosis\(^{[7,32,33]}\). The overexpression of constitutively active FOXO3a can induce BIM expression and apoptosis in the presence of survival signaling\(^{[31]}\). Akt phosphorylates FOXO3a at Thr 32, Ser 253, and Ser 315\(^{[34,35]}\), resulting in its nuclear exclusion and its association with 14-3-3, which can further block FOXO3a inactivation through multiple signaling pathways, a possibility that requires further investigation in future studies.

Activated Akt (p-Akt) can block apoptosis by inactivating several targets, including Bad, forkhead transcription factors, or caspase-9\(^{[30]}\). In this investigation, LY294002 attenuated STS-mediated protection, indicating that PI3K/Akt pathway plays an important role in the protective effect elicited by STS. One issue that was also addressed in this study is that p-Akt is partially inhibited by LY294002 (Figure 3). Thus, this study demonstrates that STS activates Akt by inducing its phosphorylation. Then, activated p-Akt phosphorylates and inactivates FOXO3A, which alleviates the apoptosis driven by a Bim-mediated signaling pathway. However, this finding is just the tip of the iceberg. As described by Alloatti G et al\(^{[31]}\), the anti-apoptotic effect can also be blocked by inhibiting the PKC, PI3K, or ERK1/2 pathways. Therefore, it is possible that the protective effect elicited by STS might be mediated by multiple signaling pathways, a possibility that requires further investigation in future studies.
was accompanied by significant decreases in the expression of one key FOXO3A target gene, the proapoptotic Bim. Thus, the possible mechanism underlying the protective effect of STS against rat myocardial ischemia-reperfusion apoptosis injury might be elicited via the activation of a PI3K/Akt/FOXO3A/Bim-mediated signaling pathway as follows: (1) The STS activates the PI3K/Akt pathway via the phosphorylation of Akt; (2) p-Akt inactivates FOXO3A through the phosphorylation of FOXO3A; (3) The phosphorylation of FOXO3A can induce its nuclear-to-cytoplasmic translocation, thereby inhibiting its transcriptional activity; and (4) The displacement of FOXO3A from the nucleus into the cytoplasm inhibits its transcriptional activity, and in turn, the expression of its downstream target molecule Bim, which is responsible for the apoptosis-related activation of caspase-3 and cytochrome c release. However, whether the activation of the PI3K/Akt/FOXO3A/Bim pathway is the only way to inhibit cardiomyocyte apoptosis during I/R remains unknown. The full characterization of other signaling pathways needs to be further investigated.

Another issue that has not been investigated in this study is whether the activities of STS require an intracellular receptor. The PI3K/Akt pathway plays an important role in I/R injury, and the possible involvement of this pathway in the cardioprotective effect of STS warrants further investigation. It is conceivable that there is a tyrosine kinase in the putative STS receptor that activates the PI3K/Akt pathway. The elucidation of this possibility will require an intensive exploration of the STS receptor.

The salient finding of this study is that STS pretreatment elicits a significant cardioprotective effect in reducing infarct size, improving cardiac function, and inhibiting apoptosis—either directly or indirectly—through the PI3K/Akt/FOXO3A/Bim pathway. These data suggest that the application of STS represents a new therapeutic modality for treating myocardial I/R injury. A complete understanding of the mechanisms underlying the protective effects of STS will greatly facilitate the realization of its clinical potential.

Acknowledgements
This study was supported by the 2012 Zhejiang Province Traditional Chinese Medicine Scientific Research Fund (A) (2012ZA015).

Author contribution
Chang-lin ZHAI designed research; Mei-qi ZHANG, and Yue-liang ZHENG performed research; Huan CHEN, Jian-feng TU, Jing-jie CHAI, Ye SHEN, and Jun-ping GUO contributed new analytical tools and reagents; Xiang-hong YANG, Shu-ren YUAN, and Liang-zhong CHEN analyzed data; Mei-qi ZHANG and Jian-hong LU wrote the paper.

Abbreviations
Sodium tanshione IIA sulfonate, STS; ischemia-reperfusion, I/R; infarction size, IS; area at risk, AAR; terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling, TUNEL; phosphatidylinositol-3-OH kinase, PI3K; forkhead box O, FOXO; heart rate, HR, the first derivative of developed pressure, dp/dt; left ventricular developed pressure, LVDP; coronary flow, CF; left ventricles, LVs; phosphatidylinositol-4,5-bisphosphate, PIP2; 3-phosphoinositide-dependent protein kinase-1, PDK1.

References
1. Choi H, Kim SH, Chun YS, Cho YS, Park JW, Kim MS. In vivo hyperoxic preconditioning prevents myocardial infarction by expressing bcl-2. Exp Biol Med 2006; 231: 463–72.
2. Tian Y, Zhang W, Xia D, Modi P, Liang D, Wei M. Postconditioning inhibits myocardial apoptosis during prolonged reperfusion via a JAK2-STAT3-Bcl-2 pathway. J Biomed Sci 2011; 18: 53.
3. Zhai CL, Zhan MQ, Zhang Y, XuHX, Wang JM, An GP, et al. Glycyrrhizin protects rat heart against ischemia-reperfusion injury through the blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacol Sin 2012; 33: 1477–87.
4. Freude B, Masters TN, Robics F, Fokin A, Kostin S, Zimmermann R, et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 2000; 32: 197–208.
5. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448–60.
6. Skurk C, Izumiya Y, Maatz H, Razeqli P, Shiojima I, Sandri M, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 2005; 280: 20814–23.
7. Yang JY, Xia W, Hu MC. Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol 2006; 29: 643–8.
8. Yang JY, Hung MC. Deciphering the role of the forkhead transcription factors in cancer therapy. Curr Drug Targets 2011; 12: 1284–90.
9. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Lev R, et al. Activation of ERK1/2 deltaRaf-1: ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene 2003; 22: 1281–93.
10. Zhou GY, Zhao BL, Hou JW, Ma GE, Xin WJ. Protective effects of sodium tanshione IIA sulfonate against adriamycin-induced lipid peroxidation in mice hearts in vivo and in vitro. Pharmacol Res 1999; 40: 487–91.
11. Shang Q, Xu H, Huang L. Tanshinine IIA: a promising natural cardioprotective agent. Evid Based Complement Alternat Med 2012. DOI: 10.1155/2012/716459.
12. Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol 2007; 121: 9–22.
13. Jiang B, Zhang L, Wang Y, Li M, Wu W, Guan S, et al. Tanshininone IIA sodium sulfonate protects against cardiotoxicity induced by doxorubicin in vitro and in vivo. Food Chem Toxicol 2009; 47: 1538–44.
14. Yang R, Liu A, Ma X, Li L, Su D, Liu J. Sodium tanshinine IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol 2008; 51: 396–401.
15. Juhasz B, Thirunavukkarasu M, Pant R, Zhan L, Penumathsa SV, Secor ER Jr, et al. Bromelain induces cardioprotection against ischemia-reperfusion injury through Akt/FOXO pathway in rat myocardium. Am J Physiol Heart Circ Physiol 2008; 294: H1365–70.
16. Penumathsa SV, Koneru S, Thirunavukkarasu M, Zhan L, Prasad K, Maulik N. Secoisolariciresinol diglucoside: relevance to angiogenesis and cardioprotection against ischemia-reperfusion injury. J Pharmacol Exp Ther 2007; 320: 951–9.
17 Penumathsa SV, Thirunavukkarasu M, Koneru S, Juhasz B, Zhan L, Pant R, et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 2007; 42: 508–16.
18 Hu X, Zhou X, He B, Xu C, Wu L, Cui B, et al. Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol 2010; 638: 84–9.
19 Sgobbo P, Pacelli C, Grattagliano I, Villani G, Cocco T. Carvedilol inhibits mitochondrial complex I and induces resistance to H2O2-mediated oxidative insult in H9C2 myocardial cells. Biochim Biophys Acta 2007; 1767: 222–32.
20 Kim CH, Hao J, Ahn HY, Kim SW. Activation of Akt/protein kinase B mediates the protective effects of mechanical stretching against myocardial ischemia-reperfusion injury. J Vet Sci 2012; 13: 235–44.
21 Hong HJ, Liu JC, Chen JJ, Chan P, Cheng TH. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway. Int J Cardiol 2012; 157: 174–9.
22 Zhang Y, Wei L, Sun D, Cao F, Gao H, Zhao L, et al. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes Obes Metab 2010; 12: 316–22.
23 Li XH, Tang RY. Relationship between inhibitory action of tanshinone on neutrophil function and its prophylactic effects on myocardial infarction. Zhongguo Yao Li Xue Bao 1999; 12: 269–72.
24 Shanghai Cooperative Group for the Study of Tanshinone IIA. Therapeutic effect of sodium tanshinone IIA sulfonate in patients with coronary heart diseases: a double blind study. J Tradit Clin Med 1984; 4: 20–4.
25 Fan HY, Yang L, Fu FH, Xu H, Meng QG, Zhu HB, et al. Cardioprotective effects of salvianolic acid a on myocardial ischemia-reperfusion injury in vivo and in vitro. Evidence-based complementary and alternative medicine. 2011; doi: 10.1155/2012/508938.
26 Zhou G, Jiang W, Zhao Y, Ma G, Xin W, Yin J, et al. Sodium tanshinone IIA sulfonate mediates electron transfer reaction in rat heart mitochondria. Biochem Pharmacol 2003; 65: 51–7.
27 Xu CQ, Cang JS, He XM. Inhibition effect of tanshinone IIA on electron current of L-calcium in rat heart cell. Acta Pharmacol Toxicol Sin 1996; 12: 85–8.
28 Wang YL, Chen NH, Ding JH. Inhibitory effects of sodium tanshinone IIA sulfonate on microsomal Na+, K+-ATPase in rat heart and brain. Acta Pharmacol Toxicol Sin 1994; 8: 19–23.
29 Zuo YJ, Li YQ, Wang G. Effect of tanshinone IIA sulfonic acid natrium injection on angina pectoris and hemorrhoeology in patients with coronary artery disease. Prog Mod Biomed 2007; 7: 732–4.
30 Zhao H, Sapolsky RM, Steinberg GK. Phosphoinositide-3-kinase/Akt survival pathways are implicated in neuronal survival after stroke. Mol Neurobiol 2006; 34: 249–70.
31 Alloatti G, Arnoletti E, Bassino E, Penna C, Perrelli MG, Ghe C, et al. Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am J Physiol Heart Circ Physiol 2010; 299: H470–81.
32 Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421–6.
33 Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC, et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 2004; 279: 1513–25.
34 Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410–25.
35 Brunet A, Bonni A, Ziqmond MJ, Lin MZ, Joo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857–68.
36 Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003; 162: 613–22.
37 Urbich C, Knau A, Fichtlscherer S, Walter DH, Bruhl T, Potente M, et al. FOXO-dependent expression of the proapoptotic protein Bim: Pivotal role for apoptosis signaling in endothelial progenitor cells. FASEB J 2005; 19: 974–6.